NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.

PLoS One · 2013 · PMC3728309 · PMID 23935925

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patel at the 2010 ASCO meeting in Chicago showed a trend toward response and clinical benefit in the patients treated with MEK 1/2 inhibitor and harboring a BRAF V600E gene mutation [11] .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.